Recordati S.p.A. (REC) — Stock analysis
EURCurrent price
51,30 €
0,15 € (+0.29%) today
Market signals
About Recordati S.p.A.
Recordati is an Italian pharmaceutical group specialising in rare diseases, urology and established branded drugs. It operates in Europe, North Africa and the Middle East. Since 2018 it has been controlled by CVC Capital Partners. The portfolio includes rare disease treatments (about 40% of revenue), urology (Urorec) and a broad base of branded drugs. Headquartered in Milan.
What does Recordati do?▾
Recordati is a pharmaceutical group specialising in rare diseases, urology and branded drugs. It primarily operates in Europe, North Africa and the Middle East. Since 2018 it has been controlled by CVC Capital Partners.
Which exchange is Recordati listed on?▾
Recordati is listed on Borsa Italiana with ticker REC. It is a member of the FTSE MIB index.
Does Recordati pay dividends?▾
Yes. It pays a progressively growing annual dividend. Yield is typically 1.5–2.5%.
Analyse this stock with AI
Create a free account and get 2 credits to generate a complete analysis.
Create account · 2 free credits